Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).

Authors: Sagar Lonial, Ho-Young Yhim, Vanesa Caruso, Jae-Cheol Jo, Sung-Hoon Jung, Youngil Koh, Peter Barth, Samineh Deheshi, Eleftheria Kalaitzaki, Brandon Kremer, Julia Boyle, Nicola Jackson, Wei Sun, Fernando Carreno, Pralay Mukhopadhyay, Joanna Opalinska, Meletios Athanasios Dimopoulos

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7567

Source: Full article

---

Abstract

TPS7567